| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Presentation Details
Title: LB-102 for acute schizophrenia in adults: efficacy and safety from a large phase 2 clinical trial
Poster Number: PS02-1273
Date: October 12, 2025
Time: 12:35 - 14:00 p.m.
Title: LB-102 for acute schizophrenia in adults: Results from the phase 2 clinical trial (NOVA1) with a focus on Negative Symptoms
Poster Number: PS02-1272
Date: October 12, 2025
Time: 12:35 - 14:00 p.m.
Title: LB-102 for cognitive impairment in schizophrenia: exploratory post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Poster Number: PS03-2276
Date: October 13, 2025
Time: 12:35 - 14:00 p.m.
Posters will be made available on the LB Pharma website at https://lbpharma.us/ on October 11, 2025, at the start of the conference.
Posted In: LBRX
